TriLink BioTechnologies LLC
TriLink BioTechnologies is committed to delivering innovative nucleic acid tools and services to advance nucleic acid therapies from research to patients. With over 25 years of experience, they provide a comprehensive portfolio of products and services including mRNA synthesis, capping, modification, and manufacturing, supporting research, pre-clinical, clinical, and commercial applications. They also offer custom chemistry, discovery mRNA synthesis, analytical services, and comprehensive analytical capabilities to support process development, scale-up, GMP manufacturing, and regulatory compliance. Their analytical services include method feasibility testing, method development and optimization, method qualification and validation, method transfer, quality control, and release, ensuring high standards in mRNA evaluation and quality assurance.
Industries
Nr. of Employees
large (251-1000)
TriLink BioTechnologies LLC
1000 N. West Street, Suite 200, Wilmington, DE 19801
Patents
Products
CleanCap Reagents and Kits
Innovative mRNA capping solutions with high efficiency and scalability.
mRNA Synthesis and Services
Custom and discovery mRNA synthesis, including long RNA, with analytical support.
Nucleoside Triphosphates (NTPs)
A wide selection of modified and GMP-grade NTPs for RNA manufacturing.
CleanCap Reagents and Kits
Innovative mRNA capping solutions with high efficiency and scalability.
mRNA Synthesis and Services
Custom and discovery mRNA synthesis, including long RNA, with analytical support.
Nucleoside Triphosphates (NTPs)
A wide selection of modified and GMP-grade NTPs for RNA manufacturing.
Services
Supporting early-stage research with catalog mRNA, CleanCap technology, NTPs, and discovery synthesis.
Supporting the transition to clinical with mRNA synthesis, plasmid DNA-to-mRNA pathway, analytical methods, and CleanCap technology.
Supporting clinical trial scale-up with GMP mRNA manufacturing, process development, and analytical services.
Providing GMP-grade reagents and technologies used in global manufacturing programs, including COVID-19 vaccines.
Supporting early-stage research with catalog mRNA, CleanCap technology, NTPs, and discovery synthesis.
Supporting the transition to clinical with mRNA synthesis, plasmid DNA-to-mRNA pathway, analytical methods, and CleanCap technology.
Supporting clinical trial scale-up with GMP mRNA manufacturing, process development, and analytical services.
Providing GMP-grade reagents and technologies used in global manufacturing programs, including COVID-19 vaccines.
News & Updates
TriLink's GMP mRNA manufacturing facility onboards clients in 2024
Expansion of GMP manufacturing capabilities to support late-phase drug development.
Over 3 billion vaccine doses administered using CleanCap technology
Global impact of TriLink's capping technology in vaccine production.
TriLink's partnership with leading pharma companies
Trusted by 10 out of 10 top global pharma companies for mRNA solutions.
Supporting the development of mRNA therapeutics and vaccines with innovative tools and services.
Over 4,000 citations of TriLink products in publications
Recognition of the scientific impact of TriLink's products.
Served over 1,000 mRNA synthesis customers
Extensive customer base supporting research and development.
TriLink's GMP mRNA manufacturing facility onboards clients in 2024
Expansion of GMP manufacturing capabilities to support late-phase drug development.
Over 3 billion vaccine doses administered using CleanCap technology
Global impact of TriLink's capping technology in vaccine production.
TriLink's partnership with leading pharma companies
Trusted by 10 out of 10 top global pharma companies for mRNA solutions.
Supporting the development of mRNA therapeutics and vaccines with innovative tools and services.
Over 4,000 citations of TriLink products in publications
Recognition of the scientific impact of TriLink's products.
Served over 1,000 mRNA synthesis customers
Extensive customer base supporting research and development.